Skip to Content
Merck
All Photos(1)

Documents

878119P

Avanti

C16 Lyso PAF

Avanti Research™ - A Croda Brand 878119P, powder

Synonym(s):

1-O-hexadecyl-2-hydroxy-sn-glycero-3-phosphocholine

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C24H52NO6P
CAS Number:
52691-62-0
Molecular Weight:
481.65
UNSPSC Code:
12352211
NACRES:
NA.25

form

powder

packaging

pkg of 1 × 5 mg (878119P-5mg)

manufacturer/tradename

Avanti Research™ - A Croda Brand 878119P

lipid type

bioactive lipids
phosphoglycerides

shipped in

dry ice

storage temp.

−20°C

SMILES string

O[C@](COP([O-])(OCC[N+](C)(C)C)=O)([H])COCCCCCCCCCCCCCCCC

InChI

1S/C24H52NO6P/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-20-29-22-24(26)23-31-32(27,28)30-21-19-25(2,3)4/h24,26H,5-23H2,1-4H3/t24-/m1/s1

InChI key

VLBPIWYTPAXCFJ-XMMPIXPASA-N

Application

C16 Lyso PAF is suitable for the use in thin layer chromatography for the synthesis of acyl-platelet activating factor (PAF). It is also suitable for intraperitoneal injection into mice to compare the relative inhibitory actions of acyl-PAF, lyso-PC and lyso-PAF on alkyl PAF-induced death.

Packaging

5 mL Amber Glass Screw Cap Vial (878119P-5mg)

Legal Information

Avanti Research is a trademark of Avanti Polar Lipids, LLC

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Modulation of inflammatory platelet-activating factor (PAF) receptor by the acyl analogue of PAF
Chaithra VH, et al.
Journal of Lipid Research, 59(11), 2063-2074 (2018)
Kelsey B Law et al.
Autophagy, 13(5), 868-884 (2017-05-20)
Peroxisome biogenesis disorders (PBDs) are metabolic disorders caused by the loss of peroxisomes. The majority of PBDs result from mutation in one of 3 genes that encode for the peroxisomal AAA ATPase complex (AAA-complex) required for cycling PEX5 for peroxisomal
Michael A Kennedy et al.
PLoS genetics, 10(1), e1004010-e1004010 (2014-01-28)
Unbiased lipidomic approaches have identified impairments in glycerophosphocholine second messenger metabolism in patients with Alzheimer's disease. Specifically, we have shown that amyloid-β42 signals the intraneuronal accumulation of PC(O-16:0/2:0) which is associated with neurotoxicity. Similar to neuronal cells, intracellular accumulation of

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service